The FAK inhibitor BI 853520 inhibits spheroid formation and orthotopic tumor growth in malignant pleural mesothelioma.


Journal

Journal of molecular medicine (Berlin, Germany)
ISSN: 1432-1440
Titre abrégé: J Mol Med (Berl)
Pays: Germany
ID NLM: 9504370

Informations de publication

Date de publication:
02 2019
Historique:
received: 12 06 2018
accepted: 19 11 2018
revised: 16 11 2018
pubmed: 13 12 2018
medline: 28 5 2020
entrez: 13 12 2018
Statut: ppublish

Résumé

No tyrosine kinase inhibitors are approved for malignant pleural mesothelioma (MPM). Preclinical studies identified focal adhesion kinase (FAK) as a target in MPM. Accordingly, we assessed the novel, highly selective FAK inhibitor (BI 853520) in 2D and 3D cultures and in vivo. IC

Identifiants

pubmed: 30539198
doi: 10.1007/s00109-018-1725-7
pii: 10.1007/s00109-018-1725-7
pmc: PMC6348072
doi:

Substances chimiques

Protein Kinase Inhibitors 0
Focal Adhesion Protein-Tyrosine Kinases EC 2.7.10.2

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

231-242

Subventions

Organisme : Austrian Science Fund FWF
ID : I 2872
Pays : Austria

Références

Cancer Biol Ther. 2018 Apr 3;19(4):316-327
pubmed: 29303405
Sci Transl Med. 2014 May 21;6(237):237ra68
pubmed: 24848258
PLoS Biol. 2010 Jun 29;8(6):e1000412
pubmed: 20613859
Cancer Lett. 2014 Jun 28;348(1-2):88-99
pubmed: 24657306
Cancer Biol Ther. 2010 May 15;9(10):764-77
pubmed: 20234191
Expert Opin Ther Pat. 2014 Oct;24(10):1077-100
pubmed: 25113248
Exp Cell Res. 2013 Dec 10;319(20):3094-103
pubmed: 23973668
Future Oncol. 2017 Dec;13(28):2537-2546
pubmed: 29086616
Oncogene. 2006 Sep 28;25(44):5960-8
pubmed: 16652148
Nat Rev Cancer. 2005 Jul;5(7):505-15
pubmed: 16069815
J Med Chem. 2008 Dec 11;51(23):7405-16
pubmed: 18989950
Nat Rev Mol Cell Biol. 2005 Jan;6(1):56-68
pubmed: 15688067
Front Pharmacol. 2018 Jan 23;9:6
pubmed: 29410625
Lancet. 2016 Apr 2;387(10026):1405-1414
pubmed: 26719230
Curr Opin Cell Biol. 1999 Oct;11(5):561-6
pubmed: 10508653
Pharmacol Ther. 2015 Feb;146:132-49
pubmed: 25316657
Br J Cancer. 2015 Mar 3;112(5):783-92
pubmed: 25633038
Cancer Res. 2009 Jan 15;69(2):466-74
pubmed: 19147559
Cancer Sci. 2017 Jul;108(7):1347-1356
pubmed: 28406574
Hum Pathol. 2003 Mar;34(3):240-5
pubmed: 12673558
Nat Med. 2016 Aug;22(8):851-60
pubmed: 27376576
Sci Signal. 2017 Dec 05;10(508):
pubmed: 29208683
J Natl Cancer Inst. 2013 Oct 2;105(19):1485-95
pubmed: 24062525
Ann Oncol. 2016 Dec;27(12):2268-2274
pubmed: 27733373
Adv Enzyme Regul. 1984;22:27-55
pubmed: 6382953
Am J Respir Crit Care Med. 2014 Oct 1;190(7):763-72
pubmed: 25188816
EMBO Rep. 2012 Mar;13(3):204-15
pubmed: 22482125
Clin Cancer Res. 2016 Aug 1;22(15):3718-24
pubmed: 27262114
J Pathol. 2015 Oct;237(2):203-14
pubmed: 26011651
PLoS One. 2015 May 01;10(5):e0119549
pubmed: 25932953
Oncogene. 2017 Sep 28;36(39):5522-5531
pubmed: 28553954
J Neurooncol. 2004 Mar-Apr;67(1-2):147-57
pubmed: 15072462
Anticancer Agents Med Chem. 2010 Dec;10(10):722-34
pubmed: 21291406
Int Rev Cytol. 2007;263:103-53
pubmed: 17725966
Chest. 2004 Oct;126(4):1318-29
pubmed: 15486399
Stem Cell Reports. 2017 Apr 11;8(4):1005-1017
pubmed: 28285878
Cell Death Differ. 2009 Aug;16(8):1146-55
pubmed: 19343038
J Clin Invest. 2016 May 2;126(5):1885-96
pubmed: 27064283
Gynecol Oncol. 2014 Jul;134(1):104-11
pubmed: 24786638
Clin Cancer Res. 2000 Jun;6(6):2417-23
pubmed: 10873094
Clin Exp Metastasis. 2015 Dec;32(8):799-817
pubmed: 26445848
Onco Targets Ther. 2017 Mar 23;10:1783-1792
pubmed: 28367061
Proc Natl Acad Sci U S A. 1995 Nov 21;92(24):10854-8
pubmed: 7479897
Breast Cancer Res. 2010;12(4):R56
pubmed: 20663194
Oncogenesis. 2018 Feb 23;7(2):21
pubmed: 29472531
J Biotechnol. 2010 Jul 1;148(1):3-15
pubmed: 20097238
Cancer Chemother Pharmacol. 2016 May;77(5):997-1003
pubmed: 27025608
J Thorac Oncol. 2013 Nov;8(11):1389-95
pubmed: 24084442

Auteurs

Viktoria Laszlo (V)

Division of Thoracic Surgery, Department of Surgery, Comprehensive Cancer Center, Medical University of Vienna, Waehringer Guertel 18-20, A-1090, Vienna, Austria.
Department of Biomedical Imaging and Image-guided Therapy, Division of Molecular and Gender Imaging, Medical University of Vienna, Vienna, Austria.

Zsuzsanna Valko (Z)

Division of Thoracic Surgery, Department of Surgery, Comprehensive Cancer Center, Medical University of Vienna, Waehringer Guertel 18-20, A-1090, Vienna, Austria.
Department of Tumor Biology, National Korányi Institute of Pulmonology, Budapest, Hungary.

Judit Ozsvar (J)

Division of Thoracic Surgery, Department of Surgery, Comprehensive Cancer Center, Medical University of Vienna, Waehringer Guertel 18-20, A-1090, Vienna, Austria.

Ildiko Kovacs (I)

Department of Tumor Biology, National Korányi Institute of Pulmonology, Budapest, Hungary.

Tamas Garay (T)

2nd Department of Pathology, Semmelweis University, Budapest, Hungary.

Mir Alireza Hoda (MA)

Division of Thoracic Surgery, Department of Surgery, Comprehensive Cancer Center, Medical University of Vienna, Waehringer Guertel 18-20, A-1090, Vienna, Austria.

Thomas Klikovits (T)

Division of Thoracic Surgery, Department of Surgery, Comprehensive Cancer Center, Medical University of Vienna, Waehringer Guertel 18-20, A-1090, Vienna, Austria.

Paul Stockhammer (P)

Division of Thoracic Surgery, Department of Surgery, Comprehensive Cancer Center, Medical University of Vienna, Waehringer Guertel 18-20, A-1090, Vienna, Austria.
Department of Thoracic Surgery, Ruhrlandklinik, University Clinic Essen, University Duisburg-Essen, Tüschener Weg 40, 45239, Essen, Germany.

Clemens Aigner (C)

Department of Thoracic Surgery, Ruhrlandklinik, University Clinic Essen, University Duisburg-Essen, Tüschener Weg 40, 45239, Essen, Germany.

Marion Gröger (M)

Core Facility Imaging, Medical University of Vienna, Vienna, Austria.

Walter Klepetko (W)

Division of Thoracic Surgery, Department of Surgery, Comprehensive Cancer Center, Medical University of Vienna, Waehringer Guertel 18-20, A-1090, Vienna, Austria.

Walter Berger (W)

Institute of Cancer Research and Comprehensive Cancer Center, Department of Medicine I, Medical University of Vienna, Vienna, Austria.

Michael Grusch (M)

Institute of Cancer Research and Comprehensive Cancer Center, Department of Medicine I, Medical University of Vienna, Vienna, Austria.

Jozsef Tovari (J)

Department of Experimental Pharmacology, National Institute of Oncology, Budapest, Hungary.
KINETO Lab Ltd, Budapest, Hungary.

Irene C Waizenegger (IC)

Boehringer Ingelheim RCV GmbH & Co KG, Vienna, Austria.

Balazs Dome (B)

Division of Thoracic Surgery, Department of Surgery, Comprehensive Cancer Center, Medical University of Vienna, Waehringer Guertel 18-20, A-1090, Vienna, Austria. balazs.dome@meduniwien.ac.at.
Department of Tumor Biology, National Korányi Institute of Pulmonology, Budapest, Hungary. balazs.dome@meduniwien.ac.at.
Department of Thoracic Surgery, National Institute of Oncology-Semmelweis University, Budapest, Hungary. balazs.dome@meduniwien.ac.at.

Balazs Hegedus (B)

Division of Thoracic Surgery, Department of Surgery, Comprehensive Cancer Center, Medical University of Vienna, Waehringer Guertel 18-20, A-1090, Vienna, Austria. balazs.hegedues@rlk.uk-essen.de.
2nd Department of Pathology, Semmelweis University, Budapest, Hungary. balazs.hegedues@rlk.uk-essen.de.
Department of Thoracic Surgery, Ruhrlandklinik, University Clinic Essen, University Duisburg-Essen, Tüschener Weg 40, 45239, Essen, Germany. balazs.hegedues@rlk.uk-essen.de.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH